BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marin JJ, Macias RI. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs. Expert Opin Investig Drugs 2021;30:675-9. [PMID: 33934687 DOI: 10.1080/13543784.2021.1916912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Shibata Y, Sudo T, Tazuma S, Tazawa H, Suzuki T, Onoe T, Shimizu Y, Tashiro H, Kuraoka K, Takahashi S. Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery. Clin J Gastroenterol 2023;16:81-6. [PMID: 36239900 DOI: 10.1007/s12328-022-01719-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Uson Junior PLS, Bearss J, Babiker HM, Borad MJ. Novel precision therapies for cholangiocarcinoma: an overview of clinical trials. Expert Opin Investig Drugs 2023;:1-7. [PMID: 36714945 DOI: 10.1080/13543784.2023.2173064] [Reference Citation Analysis]
3 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022;71:1669-83. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cadamuro M, Macias RI, Strain AJ, Strazzabosco M, Simioni P, Marin JJ, Fabris L. Unmet needs in basic and translational research in Cholangiocarcinoma. Liver Cancer International 2022;3:5-16. [DOI: 10.1002/lci2.39] [Reference Citation Analysis]
5 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2022;42:87-103. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
6 Venkatraman S, Balasubramanian B, Pongchaikul P, Tohtong R, Chutipongtanate S. Molecularly Guided Drug Repurposing for Cholangiocarcinoma: An Integrative Bioinformatic Approach. Genes 2022;13:271. [DOI: 10.3390/genes13020271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Marin JJG, Reviejo M, Soto M, Lozano E, Asensio M, Ortiz-Rivero S, Berasain C, Avila MA, Herraez E. Impact of Alternative Splicing Variants on Liver Cancer Biology. Cancers (Basel) 2021;14:18. [PMID: 35008179 DOI: 10.3390/cancers14010018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Reviejo M, Soto M, Lozano E, Asensio M, Martínez-Augustin O, Sánchez de Medina F, Marin JJG. Impact of alternative splicing on mechanisms of resistance to anticancer drugs. Biochem Pharmacol 2021;193:114810. [PMID: 34673012 DOI: 10.1016/j.bcp.2021.114810] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]